DataMeds AI agrees to acquire cancer blood test platform from Todos Medical estate
MEDS•DataMeds AI agreed to acquire TBIA cancer blood-testing assets from Todos Medical’s estate for its Helomics subsidiary, subject to court approval. The assets include breast and colorectal cancer tests with issued U.S. and European patents providing exclusivity into at least 2034; the tests are not FDA-cleared or commercially available in the United States.
1. Proposed asset acquisition
DataMeds AI agreed to acquire the TBIA cancer blood-testing assets from Todos Medical’s estate for its Helomics subsidiary, subject to court approval. Helomics plans to revalidate the breast and colorectal cancer testing platform to support a laboratory-developed test launch before FDA submissions.
2. Other assets and status
The acquisition also includes Todos’ license to the LymPro Alzheimer’s diagnostic blood test. Issued U.S. and European patents provide exclusivity for the TBIA platform into at least 2034, but the tests lack FDA clearance or approval and are not commercially available in the United States.




